- Home
- CMP vs TNGX Comparison
CMP vs TNGX Comparison
Compare CMP & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMP
- TNGX
- Stock Information
- Founded
- CMP 1993
- TNGX 2014
- Country
- CMP United States
- TNGX United States
- Employees
- CMP N/A
- TNGX N/A
- Industry
- CMP Other Metals and Minerals
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- CMP Basic Materials
- TNGX Health Care
- Exchange
- CMP Nasdaq
- TNGX Nasdaq
- Market Cap
- CMP 781.2M
- TNGX 723.2M
- IPO Year
- CMP 2003
- TNGX N/A
- Fundamental
- Price
- CMP $17.22
- TNGX $7.83
- Analyst Decision
- CMP Hold
- TNGX Strong Buy
- Analyst Count
- CMP 3
- TNGX 6
- Target Price
- CMP $20.00
- TNGX $10.80
- AVG Volume (30 Days)
- CMP 355.2K
- TNGX 4.0M
- Earning Date
- CMP 12-15-2025
- TNGX 11-04-2025
- Dividend Yield
- CMP N/A
- TNGX N/A
- EPS Growth
- CMP N/A
- TNGX N/A
- EPS
- CMP N/A
- TNGX N/A
- Revenue
- CMP $1,225,200,000.00
- TNGX $24,296,000.00
- Revenue This Year
- CMP $12.05
- TNGX $20.42
- Revenue Next Year
- CMP $4.15
- TNGX N/A
- P/E Ratio
- CMP N/A
- TNGX N/A
- Revenue Growth
- CMP 7.27
- TNGX N/A
- 52 Week Low
- CMP $8.60
- TNGX $1.03
- 52 Week High
- CMP $22.69
- TNGX $9.70
- Technical
- Relative Strength Index (RSI)
- CMP 39.68
- TNGX 47.83
- Support Level
- CMP $17.54
- TNGX $7.12
- Resistance Level
- CMP $18.91
- TNGX $9.39
- Average True Range (ATR)
- CMP 0.93
- TNGX 0.78
- MACD
- CMP -0.15
- TNGX -0.14
- Stochastic Oscillator
- CMP 9.28
- TNGX 37.87
About CMP Compass Minerals Intl Inc
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.